Latest papers

Undifferentiated spondyloarthritis: recent clinical and therapeutic advances.

Abstracts of the American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting. November 6-11, 2010. Atlanta, Georgia, USA.

Comparison of health-related quality of life and associated psychological factors between younger and older patients with established rheumatic disorders.

Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center.

Epidemiologic study of soft tissue rheumatism in Shantou and Taiyuan, China.

Geoepidemiology of autoimmune rheumatic diseases.

Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond.

Scope of inflammopharmacology.

Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism.

[Evaluation of therapeutic effects on sacroiliitis and enthesopathy in ankylosing spondylitis patients by color ultrasound].

MicroRNAs as biomarkers in rheumatic diseases.

Introduction to special section: drug safety in the rheumatic diseases.

Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.

Prevention of acute adverse events related to infliximab infusions in pediatric patients.

Infliximab and insulin resistance.

Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.

Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Self-management of rheumatic diseases: state of the art and future perspectives.

[Paraneoplastic autoimmune disorders]

[Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].